Brief: Mckesson Biologics By Mckesson Was Selected By Springworks Therapeutics As A Limited Distribution Specialty Pharmacy For Ogsiveo (Nirogacestat)
05/12/2023 16:33
Dec 5 (Reuters) - Mckesson Corp MCK.N :
* MCKESSON: BIOLOGICS BY MCKESSON WAS SELECTED BY
SPRINGWORKS
THERAPEUTICS AS A LIMITED DISTRIBUTION SPECIALTY PHARMACY FOR
OGSIVEO (NIROGACESTAT)
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on SpringWorks Therapeutics
See all newsBrief: Merck KGaA Completes Acquisition Of Springworks Therapeutics
Brief: Springworks Therapeutics Expects Nirogacestat Decision From European Commission In Q3
Brief: EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With NF1-PN